Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our FcRn Binding Kit!
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
IL10 / IL10RA mAb | Monospecific antibody | Infectious and parasitic diseases | Immunodeficiencies | PCC | Global |
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
GMP-L10H25 | Human | GMP Human IL-10 Protein |
|
||
CRS-B005 | Human | ClinMax™ Human IL-10 ELISA Kit | |||
IL0-C4248 | Cynomolgus | Cynomolgus IL-10 Protein, His Tag |
|
|
|
IL0-H5219 | Human | Human IL-10 Protein, premium grade |
|
|
|
CRS-A008 | Human | resDetect™ Human Interleukin-10 (IL-10) ELISA Kit (Residue Testing) | |||
IL0-M4248 | Mouse | Mouse IL-10 Protein, His Tag |
|
||
IL0-H4248 | Human | Human IL-10 Protein, His Tag |
|
|
GMP Human IL-10 Protein (Cat. No. GMP-L10H25) inhibits the secretion IL-6 by RAW264.7 cells. The specific activity of GMP Human IL-10 Protein is > 1.00 x 10^7 IU/mg, which is calibrated against WHO Reference Reagent Interleukin-10 (Human, rDNA derived) (NIBSC code: 93/722) (QC tested).
Human IL-10, premium grade (Cat. No. IL0-H5219) inhibits the secrection IL-6 by RAW264.7 cells. The specific activity of Human IL-10, premium grade is >1.00 x 10^7 IU/mg, which is calibrated against WHO Reference Reagent Interleukin-10 (Human, rDNA derived) (NIBSC code: 93/722) (QC tested).
Immobilized Human IL-10, premium grade (Cat. No. IL0-H5219) at 5 μg/mL (100 μL/well) can bind Biotinylated Human IL-10 R alpha, Fc,Avitag (Cat. No. ILR-H82F6) with a linear range of 0.2-5 ng/mL (QC tested).
The purity of Human IL-10, premium grade (Cat. No. IL0-H5219) is more than 90% and the molecular weight of this protein is around 35-45 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Mesenchymal stem cells therapy (Therapeutic Solutions International) | Phase 3 Clinical | Jadi Cell LLC | Coronavirus Disease 2019 (COVID-19) | Details | |
KLS-2031 | KLS-2031 | Phase 2 Clinical | Kolon Life Science. Inc | Radiculopathy | Details |
WP-1303 (worgpharma) | ATX-MS-1467; ATX-MS-01; M-2736; WP-1303; MSC-2358825A | Phase 2 Clinical | Apitope Technology | Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Multiple Myeloma | Details |
XT-150 | XT-101-R; XT-101; XT-150 | Phase 2 Clinical | Xalud Therapeutics Inc | Multiple Sclerosis; Neuralgia; Back Pain; Osteoarthritis, Knee; Arthralgia; Inflammation; Osteoarthritis, Spine | Details |
Mesenchymal stem cells therapy (Therapeutic Solutions International) | Phase 3 Clinical | Jadi Cell LLC | Coronavirus Disease 2019 (COVID-19) | Details | |
KLS-2031 | KLS-2031 | Phase 2 Clinical | Kolon Life Science. Inc | Radiculopathy | Details |
WP-1303 (worgpharma) | ATX-MS-1467; ATX-MS-01; M-2736; WP-1303; MSC-2358825A | Phase 2 Clinical | Apitope Technology | Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Multiple Myeloma | Details |
XT-150 | XT-101-R; XT-101; XT-150 | Phase 2 Clinical | Xalud Therapeutics Inc | Multiple Sclerosis; Neuralgia; Back Pain; Osteoarthritis, Knee; Arthralgia; Inflammation; Osteoarthritis, Spine | Details |
This web search service is supported by Google Inc.